general transcription factor IIBGenealiases: TF2B · TFIIB
Q-omics provides the consensus-scored GTF2B profile across patient tissues and cancer cell-line models. GTF2B expression is associated with patient survival in 28 of 34 cancer types, with the highest sampling consensus in KIRC. Among the 18 cancer types available for tumor–normal comparison, GTF2B is differentially expressed in 11, with the highest sampling consensus in KICH. Additionally, GTF2B protein abundance shows 18,954 significant protein co-abundance associations, with the highest sampling consensus in GBM. Together, these results highlight KIRC, KICH, and GBM as cancer lineages where GTF2B shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for GTF2B — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes GTF2B survival associations across molecular data types. GTF2B RNA expression shows survival associations in the most cancer types (28), followed by mutation status (3) and mass-spec protein abundance (4). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible GTF2B RNA expression–survival associations across cancer types. High GTF2B expression shows unfavorable associations in LIHC, LAML and LGG, but favorable associations in KIRC, CHOL and MESO. The KIRC Kaplan–Meier curve shows clear separation, with the low-expression group declining faster, consistent with the favorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRC as the clearest survival context for GTF2B RNA expression.
This table summarizes GTF2B tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 11, while mass-spec protein shows differences in 7. The strongest signals are observed in KICH for RNA and LSCC for protein.
This table ranks reproducible tumor–normal expression differences for GTF2B. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. GTF2B shows lower tumor expression in KICH and LUSC and higher tumor expression in LIHC, CHOL, ESCA and STAD. The KICH box plot shows higher GTF2B RNA expression in normal versus tumor tissue (log2 FC = −1.719, t-test p < 0.001).
This table shows molecular features associated with GTF2B in patient tissues and cancer cell lines. In patient samples, GTF2B shows the broadest associations at the RNA and protein expression levels, with GBM recurring as the lineage with the largest associated feature set. In cancer cell lines, GTF2B RNA and mutation anchors are most strongly linked to RNA-expression features, especially in LARGE_INTESTINE, while CRISPR and shRNA rows add functional-dependency signals in SKIN and BLOOD_Leukemia.
